Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1

Conditions

Neoplasms 3Skin Carcinoma 1Patient Satisfaction 1Melanoma 1Hematologic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Aftercare × Clear all
NCT03943082 2021-11-16

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

University of California, San Francisco

Phase NA Terminated
252 enrolled
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02637349 2019-11-26

POST

Polaris Health Directions

Phase 2 Completed
200 enrolled
Tumor-Agnostic

Neoplasms

NCT02440737 2019-10-18

NEST

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
67 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡